MedPath

Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders

Not Applicable
Not yet recruiting
Conditions
Language Development Disorders
Interventions
Diagnostic Test: acoustic otoemisions
Diagnostic Test: Otoscopy
Diagnostic Test: Audiometry
Diagnostic Test: Tympanometry
Registration Number
NCT05624983
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

Among the objective non-invasive audiological explorations the distorsion products of otoacoustic emissions (DPOAE) allow to quickly assess the function of the cochlear outer hair cells (without the active participation of the subject). This technique is used in newborn screening. While humans are able to perceive sounds in a frequency range of 20Hz to 20kHz, routine clinical audiological assessment is only concerned with frequencies between 1-4kHz.

This obscures the importance of high frequencies (HF) which can be easily assessed by DPOAEs. In young children, the perception of these high frequencies could also play an important role in language acquisition.

The main objective of this study is to evaluate the relationship between subtle high-frequency hearing impairment, as assessed by the DPOAE (non-invasive, rapid and simple audiological test), and language delay or difficulties in a pre-, peri- and school-age pediatric population.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
138
Inclusion Criteria

Not provided

Exclusion Criteria
  • Hearing disorder identified during the inclusion visit (presence of cerumen or foreign body in the earwax plug or foreign body in the external auditory canal, tympanometry suggesting a middle ear disorder, audiometry with thresholds outside the normal thresholds outside the normal range (0-20dB HL), absence of responses in (0-20dB HL), absence of responses in acoustic otoemissions or acoustic distortion products) on conversational frequencies between 500Hz and 4kHz.
  • Declaration by the parents of an ENT follow-up for a hearing disorder and/or a speech therapy for a language disorder
  • Refusal of participation evoked by the subject

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Case group (children with language disorder)acoustic otoemisionsHearing diagnostic test
Case group (children with language disorder)OtoscopyHearing diagnostic test
controle group (children without language disorder)acoustic otoemisionsHearing diagnostic test
controle group (children without language disorder)TympanometryHearing diagnostic test
Case group (children with language disorder)TympanometryHearing diagnostic test
controle group (children without language disorder)OtoscopyHearing diagnostic test
controle group (children without language disorder)AudiometryHearing diagnostic test
Case group (children with language disorder)AudiometryHearing diagnostic test
Primary Outcome Measures
NameTimeMethod
HF DPOAE measurementDay 1

at frequencies 4265, 4688, 5154, 5666, 6229, 6847, 7527, 8275, 9096 and 10000 Hz

Secondary Outcome Measures
NameTimeMethod
Presence or absence of HF DPOAEDay 1

assessed by tympanometry, categorisation of this categorisation of this into 3 classes A, B and C frequency will be defined by a signal to noise ratio \> 6 dB. The absence of DPOAE for each frequency will be defined by a signal to noise ratio ≤ 6 dB.

Laterality of hearing loss at the DPOAE level with a classification into 3 groupsDay 1

Not affected bilaterally affected, unilateral affected, bilateral affected; one side is considered to be affected if at least one of the at least one of the HF DPOAEs is ≤ 6 dB.

Determination of the average hearing loss (baseline pure tone audiometry)Day 1

according to the BIAP, average of audiometric thresholds at 500Hz thresholds at 500Hz, 1kHz, 2kHz and 4kHz

Severity and type of language impairment assessed by the EVALO/ EVALEOday 1

assessment and scoring by speech and language therapists

Functional status of the middle earDay 1

assessed by tympanometry, categorisation of this categorisation of this into 3 classes A, B and C

Trial Locations

Locations (1)

CHU Clermont-Ferrand, UMR INSERM 1107

🇫🇷

Clermont-Ferrand, France

© Copyright 2025. All Rights Reserved by MedPath